Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Olema Pharmaceuticals Inc (OLMA)

Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,863,433
  • Shares Outstanding, K 68,660
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,470 K
  • EBIT $ -165 M
  • EBITDA $ -165 M
  • 60-Month Beta 1.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.52

Options Overview Details

View History
  • Implied Volatility 87.49% (+5.93%)
  • Historical Volatility 82.55%
  • IV Percentile 12%
  • IV Rank 7.05%
  • IV High 773.50% on 04/04/25
  • IV Low 35.47% on 09/02/25
  • Expected Move (DTE 32) 5.27 (19.42%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,016
  • Volume Avg (30-Day) 560
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 24,176
  • Open Int (30-Day) 25,126
  • Expected Range 21.87 to 32.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.53
  • Number of Estimates 6
  • High Estimate -0.47
  • Low Estimate -0.59
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -3.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.85 +13.79%
on 01/06/26
35.13 -22.74%
on 12/17/25
-7.14 (-20.83%)
since 12/16/25
3-Month
6.65 +308.12%
on 10/20/25
36.26 -25.15%
on 12/16/25
+17.54 (+182.71%)
since 10/16/25
52-Week
2.86 +848.95%
on 04/07/25
36.26 -25.15%
on 12/16/25
+21.86 (+414.02%)
since 01/16/25

Most Recent Stories

More News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 27.14 (-7.02%)
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 27.14 (-7.02%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 27.14 (-7.02%)
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.  (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 27.14 (-7.02%)
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 27.14 (-7.02%)
Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here?

Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.

OLMA : 27.14 (-7.02%)
RHHBY : 54.2500 (+0.24%)
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 27.14 (-7.02%)
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 27.14 (-7.02%)
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer Initiated OPERA-02 Phase 3 trial of palazestrant...

OLMA : 27.14 (-7.02%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 27.14 (-7.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California....

See More

Key Turning Points

3rd Resistance Point 31.21
2nd Resistance Point 30.35
1st Resistance Point 28.75
Last Price 27.14
1st Support Level 26.29
2nd Support Level 25.43
3rd Support Level 23.83

See More

52-Week High 36.26
Last Price 27.14
Fibonacci 61.8% 23.50
Fibonacci 50% 19.56
Fibonacci 38.2% 15.62
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar